GlobeNewswire

BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
11/12/2025
Ad hoc announcement pursuant to Art. 53LR BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first [...]
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
11/12/2025
Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand [...]
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
11/12/2025
TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced [...]
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/12/2025
DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“ [...]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
10/12/2025
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of [...]
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/12/2025
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
10/12/2025
– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback [...]
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
10/12/2025
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion [...]
Clearmind Medicine Announces 1-for-40 Reverse Share Split
10/12/2025
Vancouver, Canada, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Intuitive Announces Expanded Indications for da Vinci SP
10/12/2025
FDA clearance expands da Vinci SP indications to include inguinal hernia repair, cholecystectomy, and appendectomy SUNNYVALE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology [...]
DLH Reports Fiscal 2025 Fourth Quarter Results
10/12/2025
ATLANTA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science [...]
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
10/12/2025
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing [...]
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
10/12/2025
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients [...]
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
10/12/2025
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy [...]
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
10/12/2025
Newton Biocapital enters as new investor, strong participation of existing investors Pivotal Phase 2b trial initiation in 2027 of BIOX-101 to treat intracerebral hemorrhage BIOX-101 may be commercialized as early as H2 [...]
Bioxodes lève 5,5 millions d'euros dans le cadre d'une extension de la Série A afin de poursuivre la préparation d’un essai pivot pour son candidat-médicament innovant dans le traitement de l'AVC
10/12/2025
Newton Biocapital entre au capital en tant que nouvel investisseur, importante participation des investisseurs historiques Lancement en 2027 d’un essai pivot de phase 2b portant sur BIOX-101 dans le traitement de l’AVC [...]
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
10/12/2025
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile pharma collaboration [...]
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
10/12/2025
New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population [...]
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
10/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum